Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study

Female treatment with oxytocin and placebo significantly improves their male partners’ sexual quality of life and evaluation of female partner’s sexual performance. No differences between oxytocin and placebo were found across the study outcome parameters.

Like Comment

Volume 107, Issue 3, Pages 781–787

Authors:

Dana A. Muin, M.D., M.Sc., F.E.C.S.M., Safoura Sheikh Rezaei, M.D., Max Tremmel-Scheinost, M.D., Mohamed Salama, Ph.D., M.D., Anton Luger, Ph.D., M.D., Michael Wolzt, Ph.D., M.D., Peter W. Husslein, Ph.D., M.D., Michaela Bayerle-Eder, Ph.D., M.D., F.E.C.S.M.

Abstract:

Objective

To study sexual function, quality of life, and depression in men, whose female partners are undergoing double-blind placebo-controlled randomized treatment for hypoactive sexual desire disorder (HSDD).

Design

Open prospective cohort study of 22 weeks.

Setting

Academic medical center.

Patient(s)

Male partners of 30 premenopausal and postmenopausal women with HSDD.

Intervention(s)

Baseline, 3-month, and 5-month assessment (for 8 weeks each) of male response to female partner's use of oxytocin nasal spray (32 IE) and placebo within 50 minutes before sexual intercourse.

Main Outcome Measure(s)

Primary outcome parameters were Sexual Life Quality Questionnaire-Male, Sexual Activity Record, Partner Performance Questionnaire, and Hamilton Depression Scale.

Result(s)

Male Sexual Life Quality questionnaire improved significantly from −7.4 ± 9.9 at baseline to 8.2 ± 12 with female partners' treatment with oxytocin nasal spray and to 10.8 ± 13.8 with placebo. Frequency of intercourse improved slightly but not significantly from 6.3 ± 3.9 at baseline to 7.3 ± 4 with female oxytocin therapy, but not with placebo. Male desire and arousal remained stable throughout the study period. Evaluation of female partners' performance by men improved significantly from 8.9 ± 2.8 at baseline to 10.6 ± 2.2 with oxytocin and to 11.2 ± 2.6 with placebo.

Conclusion(s)

Female treatment with either oxytocin or placebo for HSDD significantly improves male sexual quality of life and evaluation of female partner's sexual performance with no difference between oxytocin and placebo on any outcome parameters. A nonsignificant improvement was seen in the frequency of intercourse, male arousal, desire, satisfaction, and Hamilton depression scale.

Clinical Trial Registration Number

NCT02229721.


Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.